Easy-to-use and highly accurate medical software for quantitative assessment of impairments in neurologically injured people.

ended

Neurological disorders, caused by either stroke, multiple sclerosis (MS) or Parkinson’s diseases affect more than 30M people worldwide. Currently, Europe has the greatest percentage of population aged 65 or over (25%) and these numbers are expected to drastically grow (3% per year) increasing the population affected by these chronic conditions. Neurological rehabilitation is an expensive doctor-supervised program designed for treating these diseases. However, there is currently no effective assessment to objectively measure and monitor the rehabilitation progress. Current solutions for performing assessments do not provide clinical evidences of their validity, show lack of accuracy and are limited to one disease type. ReHaptix has developed a medical software, designed for remote quantitative assessment of impairments in neurologically injured people. ReHaptix has developed 9 tests so far, of which 4 have been clinically validated (the gold standard), and 5 are currently under clinical validation. Healthcare Professionals (HCPs) can use the ReHaptix tests to evaluate their patients in the hospital, rehabilitation clinic or private practice, or patients can perform the tests autonomously at home on a touchscreen tablet, which empowers them about their recovery. Furthermore, patients can remotely share their results with their HCPs, who can adapt the treatment and medication, or schedule medical appointment and home-setting assessments as required. During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. During the second phase of innovation project, ReHaptix will optimize the software increasing the number of tests and developing a functional mHealth app. Clinical trials will then be initiated to obtain the CE mark as a medical device.